Loperamide: a pharmacological review.

Daniel E Baker
{"title":"Loperamide: a pharmacological review.","authors":"Daniel E Baker","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Loperamide is an antidiarrheal medication approved for the control of diarrhea symptoms and is available without a prescription. Loperamide works by a number of different mechanisms of action that decrease peristalsis and fluid secretion, resulting in longer gastrointestinal transit time and increased absorption of fluids and electrolytes from the gastrointestinal tract. It is a phenylpiperidine derivative with a chemical structure similar to opiate receptor agonists such as diphenoxylate and haloperidol. It was designed to maintain the antidiarrheal activity of these drugs, but minimize the negative aspects associated with their effects on the opiate receptor. Because of loperamides's low oral absorption and inability to cross the blood-brain barrier, it has minimal central nervous system effects. It also has a longer duration of action than diphenoxylate. However, it has no clinically significant analgesic activity and does not decrease the pain associated with some forms of irritable bowel syndrome and diarrhea. Loperamide is metabolized by the cytochrome P450 (CYP) system and is a substrate for the CYP3A4 isoenzyme. Concurrent administration with CYP3A4 inhibitors may elevate loperamide concentrations. Common adverse reactions to loperamide include cramps and nausea. Loperamide is an effective treatment for patients with painless diarrhea and is considered to be free of abuse potential.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"7 Suppl 3 ","pages":"S11-8"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in gastroenterological disorders","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Loperamide is an antidiarrheal medication approved for the control of diarrhea symptoms and is available without a prescription. Loperamide works by a number of different mechanisms of action that decrease peristalsis and fluid secretion, resulting in longer gastrointestinal transit time and increased absorption of fluids and electrolytes from the gastrointestinal tract. It is a phenylpiperidine derivative with a chemical structure similar to opiate receptor agonists such as diphenoxylate and haloperidol. It was designed to maintain the antidiarrheal activity of these drugs, but minimize the negative aspects associated with their effects on the opiate receptor. Because of loperamides's low oral absorption and inability to cross the blood-brain barrier, it has minimal central nervous system effects. It also has a longer duration of action than diphenoxylate. However, it has no clinically significant analgesic activity and does not decrease the pain associated with some forms of irritable bowel syndrome and diarrhea. Loperamide is metabolized by the cytochrome P450 (CYP) system and is a substrate for the CYP3A4 isoenzyme. Concurrent administration with CYP3A4 inhibitors may elevate loperamide concentrations. Common adverse reactions to loperamide include cramps and nausea. Loperamide is an effective treatment for patients with painless diarrhea and is considered to be free of abuse potential.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
洛哌丁胺:药理学综述。
洛哌丁胺是一种被批准用于控制腹泻症状的止泻药,无需处方即可获得。洛哌丁胺通过多种不同的作用机制起作用,减少蠕动和液体分泌,导致胃肠道运输时间延长,增加胃肠道对液体和电解质的吸收。它是一种苯基哌啶衍生物,其化学结构类似于阿片受体激动剂,如苯基哌啶酸盐和氟哌啶醇。它的目的是维持这些药物的止泻活性,但尽量减少与它们对阿片受体的影响有关的负面影响。由于洛哌丁胺口服吸收量低且不能穿过血脑屏障,它对中枢神经系统的影响很小。它的作用时间也比地芬诺酯长。然而,它没有临床显著的镇痛活性,也不能减轻与某些形式的肠易激综合征和腹泻相关的疼痛。洛哌丁胺由细胞色素P450 (CYP)系统代谢,是CYP3A4同工酶的底物。同时使用CYP3A4抑制剂可提高洛哌丁胺浓度。洛哌丁胺常见的不良反应包括痉挛和恶心。洛哌丁胺是治疗无痛性腹泻的有效药物,被认为没有滥用的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Third Eye Retroscope: rationale, efficacy, challenges. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Definitive therapy for internal hemorrhoids--new opportunities and options. Infectious disease. Early loss of immune cells and progressive immunodeficiency in HIV infection: it's all about the gut. Diarrhea. Enterotoxigenic Bacteroides fragilis: newly recognized cause of inflammatory diarrhea.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1